2SE-56194-38273

4 vaccinations 1 coded response 5 check-ins 0 free-text entries 0 call cases

Sex: Female
Age at first dose: 36-40
ZIP prefix: 220 / VA
Registered: 2021-08-02

Relationship: Self
Race: Black or African American
Ethnicity: Not Hispanic or Latino

Registered dependents

ARD-30576-36738 Child or adolescent in my care · Male · 2022-01-07

PWP-11854-80484 Child or adolescent in my care · Male · 2022-01-07

Timeline

Registration Vaccinations Survey responses Call reports Cases without a report Call attempts Call successful Pregnancy survey

2021-02-02
Dose 1 — Pfizer-BioNTech
2021-03-02
Dose 2 — Pfizer-BioNTech
2021-08-02
Registered in v-safe
2022-01-06
Dose 3 — Pfizer-BioNTech
2022-01-13
Health check-in — day 7, dose 3
Feeling: Good · Headache, Muscle or body aches · Be unable to work or attend school

Adult check-in
2023-01-11
Dose 4 — Pfizer-BioNTech
2023-01-11
Health check-in — 12 months, dose 3
Feeling: Good

Adult check-in
2023-01-11
Health check-in — day 0, dose 4
Feeling: Good · None

Adult check-in
2023-01-15
Survey response — days 1–6 daily, dose 4
MedDRA: No adverse event — Feeling: Good

MedDRA releases: 2024-11
2023-01-16
Health check-in — days 1–6 daily, dose 4
Feeling: Good · None

Adult check-in

Vaccinations

Dose	Date	Manufacturer	Co-administered
1	2021-02-02	Pfizer-BioNTech	No
2	2021-03-02	Pfizer-BioNTech	No
3	2022-01-06	Pfizer-BioNTech	No
4	2023-01-11	Pfizer-BioNTech	No

Free text

None.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

Field	Preferred term	2021-09	2023-04	2024-11
SRO	No adverse event	·	·	✓

✓ active code · ○ coded but marked inactive · blank = not in that release